3 research outputs found
Prevalence of Lumbo-Pelvic Pain in Pregnant Women of Third Trimester in Lahore Pakistan
BACKGROUND: Lower back and pelvic girdle symptoms are a common problem during pregnancy. Lumbo-pelvic pain is known to have detrimental effects on quality of life in pregnant women in many domains including physical activity, travel, social relationships, and emotional health.
OBJECTIVE: The purpose of this study is to determine the prevalence of lumbo-pelvic pain among pregnant women in their third trimester from Lahore.
METHODS: This cross-sectional short survey was conducted at Lady Aitcheson and Lady Willington Hospitals Lahore. A total no of 560 pregnant women in third trimester took part in the study.
RESULTS: Pregnant women included in this study showed 40.6% of lumbo-pelvic pain and 59.4% with no lumbo-pelvic pain. The prevalence of lumbar pain was more prevalent among all three components of lumbo-pelvic pain.
CONCLUSION: The findings of this study clearly indicated that prevalence of lumbo-pelvic pain is more significant in pregnancy. The point prevalence of lumbo-pelvic pain is 62.1%. Increased abdominal weight and hormonal changes put more burdens on the pelvic and lower back
Recommended from our members
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.
When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments